Share
Consumption analyses
The statistics and analysis area has been transferred to Statens Serum Institute, SSI, where reports are available in Danish: Lægemiddelstatistikker (Drug statistics)
You can still download previously issued reports in English:
-
01 February 2005
Potentially inappropriate prescription of the asthma product Singulair®
The asthma product Singulair® was put on the Danish market in February 1998 and became eligible for general reimbursement 13 July 1998. The medicinal product is recommended as a supplement for treatment of mild to moderate asthma as well as for exercise-induced asthma.
-
25 January 2005
Consumption of antipsychotics in Denmark among the elderly
The Danish consumption of antipsychotics among elderly people aged 65 years or above is studied for the period 1996 and 1999-2003. The number of elderly people aged 65 years or above treated with antipsychotics has fallen, whereas the quantity consumption has risen.
-
29 October 2004
Consumption of strong analgesics (opioids) in the primary sector Denmark 1999-2003
The study describes the development of the use of strong analgesics (opiods incl. codeine) from 1999 to 2003 in the primary sector. The quantity consumption of opiods has increased by 25.1 per cent during this period from 18.6 DDD/1.000 inhabitants/day in 1999 to 23.2 DDD/1.000 inhabitants/day in 2003.
-
29 October 2004
Development of benzodiazepine consumption in Denmark 1996-2003
The benzodiazepine consumption has declined over many years, and this development continues in 2003. During the 8-year study period, the consumption of benzodiazepines as sleeping medicine and sedatives halved from 30.8 to 15.4 DDD/1.000 inhabitants/day
-
17 August 2004
Treatment of blood clots with platelet function inhibitors
The rising expenses of platelet function inhibitors are caused by several factors. In general, the consumption of these medicinal products is increasing, which is due to the fact that, both in relative and absolute terms, more people start treatment with platelet function inhibitors.
-
06 July 2004
Sale of medicinal products for the treatment of erectile dysfunction
This study sheds light on the development of the use of medicinal products for the treatment of erectile dysfunction in the period between 1998 and 2003. In october 1998, Viagra® was put on the market, and since then the sale of medicinal products for the treatment of erectile dysfunction has increased rapidly.
-
11 June 2004
Consumption of antidepressants in Denmark in the primary health sector in the period 1994-2003
Antidepressant is the designation for medicinal products for depression. At some point in life, approxiamtely 15 per cent of the Danish population will be diagnosed with depression (The Danish Medicinal Product catalogue 2003) - women twice as often as men.
-
09 October 2003
Note on products for Alzheimer's disease in Denmark
This study sheds light on the development of the use of medicinal products for Alzheimer's disease during the period September 1997 until April 2003. Four medicinal products are used for treating Alzheimer's disease - 3 cholinesterase inhibitors (Aricept®, Exelon® and Reminyl®) and a glutamine
-
30 September 2003
The sale of the anti-cholinergic agent Spiriva®
Since Spiriva® was introduced on the market in the second quarter of 2002, there has been a great increase in both the consumption and prevalence of the agent among the elderly.
-
22 May 2003
Investigation of pharmacies' dispense practice
The purpose of the present investigation is to shed light on the variations in pharmaceutical companies' market shares at individual pharmacies and to investigate whether these differences mean that the dispense practice is inappropriate or expensive.
-
01 April 2003
Hoarding of medicinal products in the need-dependent reimbursement system
This analysis indicates that hoarding is a problem within the need-dependent reimbursement system. Among medicine users with expenses exceeding DKK 510 within a reimbursement year, hoarding is estimated to constitute approximately 2 per cent of the users' reimbursable medicine expenses.
